Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
Go back to Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer| (NASDAQ: RVMD) | Delayed: 193.18 +3.94 (2.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $189.24 | 52 Week High | $ | |||
| Open | $192.25 | 52 Week Low | $ | |||
| Day High | $193.69 | P/E | N/A | |||
| Day Low | $189.26 | EPS | $ | |||
| Volume | 547,748 | |||||
